CMS Endorses Combined Pap/HPV Testing, Piper Jaffray Notes (HOLX) (QGEN) (BDX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Piper Jaffray Maintains a Neutral Rating on Qiagen (QGEN) Following Expanded Channel Checks
July 14, 2015 8:02 AM EDTPiper Jaffray maintains a Neutral rating and $24.00 price target on Qiagen NV (NASDAQ: QGEN) following expanded channel checks. Analyst William Quirk says that the latest checks did not uncover additional transitions from Qiagen to alternative HPV platforms, and views this as a sighn that shares are stabilizing.
Quirk commented,... More
Piper Jaffray Downgrades Hologic (HOLX) to Neutral
July 14, 2015 6:36 AM EDTPiper Jaffray downgraded Hologic (NASDAQ: HOLX) from Overweight to Neutral with a price target of $38.00 on valuation.
Analyst William Quirk commented, "Our fundamental turnaround thesis on Hologic remains intact, however, with HOLX shares trading north of 20x FY16E, we believe shares... More
